1 Min Read
Dec 28 (Reuters) - Galena Biopharma Inc :
* Galena Biopharma confirms regulatory pathway for GALE-401 (anagrelide controlled release)
* "remain on track to initiate trial in Q2 of 2017"
* Galena Biopharma Inc- company expects to finalize phase 3 clinical trial protocol and initiate trial in Q2, 2017 for GALE-401
* Galena Biopharma Inc - company has confirmed regulatory pathway to advance GALE-401 into a pivotal, Phase 3 trial Source text for Eikon: Further company coverage: